4.0 Article

Apolipoprotein B-100-mediated motor neuron degeneration in sporadic amyotrophic lateral sclerosis

期刊

BRAIN COMMUNICATIONS
卷 4, 期 4, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/braincomms/fcac207

关键词

apolipoprotein B-100; sporadic amyotrophic lateral sclerosis; CSF; neurodegeneration; neurotoxicity

资金

  1. Laurence and Sandi Gluck Charitable Foundation

向作者/读者索取更多资源

This study demonstrates that apolipoprotein B-100 induces motor disability and motor neuron degeneration in a novel cerebrospinal fluid-mediated mouse model of sporadic amyotrophic lateral sclerosis. Targeted removal of apolipoprotein B-100 in cerebrospinal fluid attenuates its neurotoxic capacity, thereby preventing disability and motor neuron degeneration.
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by motor neuron degeneration. Approximately 90% of cases occur sporadically with no known cause while 10% are familial cases arising from known inherited genetic mutations. In vivo studies have predominantly utilized transgenic models harbouring amyotrophic lateral sclerosis-associated gene mutations, which have not hitherto elucidated mechanisms underlying motor neuron death or identified therapeutic targets specific to sporadic amyotrophic lateral sclerosis. Here we provide evidence demonstrating pathogenic differences in CSF from patients with sporadic amyotrophic lateral sclerosis and familial amyotrophic lateral sclerosis patients with mutations in SOD1, C9orf72 and TARDBP. Using a novel CSF-mediated animal model, we show that intrathecal delivery of sporadic amyotrophic lateral sclerosis patient-derived CSF into the cervical subarachnoid space in adult wild-type mice induces permanent motor disability which is associated with hallmark pathological features of amyotrophic lateral sclerosis including motor neuron loss, cytoplasmic TDP-43 translocation, reactive astrogliosis and microglial activation. Motor impairments are not induced by SOD1, C9orf72 or TARDBP CSF, although a moderate degree of histopathological change occurs in C9orf72 and TARDBP CSF-injected mice. By conducting a series of CSF filtration studies and global proteomic analysis of CSF, we identified apolipoprotein B-100 in sporadic amyotrophic lateral sclerosis CSF as the putative agent responsible for inducing motor disability, motor neuron degeneration and pathological translocation of TDP-43. Apolipoprotein B-100 alone is sufficient to recapitulate clinical and pathological outcomes in vivo and induce death of human induced pluripotent stem cell-derived motor neurons in vitro. Targeted removal of apolipoprotein B-100 from sporadic amyotrophic lateral sclerosis CSF via filtration or immunodepletion successfully attenuated the neurotoxic capacity of sporadic amyotrophic lateral sclerosis CSF to induce motor disability, motor neuron death, and TDP-43 translocation. This study presents apolipoprotein B-100 as a novel therapeutic target specific for the predominant sporadic form of amyotrophic lateral sclerosis and establishes proof-of-concept to support CSF pheresis as a therapeutic strategy for mitigating neurotoxicity in sporadic amyotrophic lateral sclerosis. Using a novel CSF-mediated mouse model of sporadic amyotrophic lateral sclerosis, Wong et al. demonstrate that apolipoprotein B-100 induces motor disability and motor neuron degeneration. Targeted depletion of apolipoprotein B-100 in CSF via immunodepletion or CSF filtration attenuates its neurotoxic capacity, thereby preventing induction of disability and motor neuron degeneration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据